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Abstract
Background: Sarcopenia is defined as the loss of muscle mass and strength with age. Although a number of adult 
influences are recognised, there remains considerable unexplained variation in muscle mass and strength between 
older individuals. This has focused attention on influences operating earlier in life. Our objective for this study was to 
identify life course influences on muscle mass and strength in an established birth cohort and develop methodology 
for collection of muscle tissue suitable to investigate underlying cellular and molecular mechanisms.
Methods: One hundred and five men from the Hertfordshire Cohort Study (HCS), born between 1931 and 1939 who 
have historical records of birth weight and weight at one year took part in the Hertfordshire Sarcopenia Study (HSS). 
Each participant consented for detailed characterisation of muscle mass, muscle function and aerobic capacity. In 
addition, a muscle biopsy of the vastus lateralis using a Weil-Blakesley conchotome was performed. Data on muscle 
mass, function and aerobic capacity was collected on all 105 participants. Muscle biopsy was successfully carried out in 
102 participants with high rates of acceptability. No adverse incidents occurred during the study.
Discussion: The novel approach of combining epidemiological and basic science characterisation of muscle in a well 
established birth cohort will allow the investigation of cellular and molecular mechanisms underlying life course 
influences on sarcopenia.
Background
Skeletal muscle is central to physical as well as metabolic
capability however, sarcopenia, the loss of muscle mass
and strength with age impairs the maintenance of these
capabilities into later life. Sarcopenia is associated with
multiple adverse outcomes for the older person from
impaired mobility and disability [1,2] morbidity from
impaired glucose tolerance as well as diabetes [3], falls
[4], fractures [5], and contributes to increased health care
costs [6] and mortality [7,8]. The predicted rise in the
number of older people over the age of 65 in the next two
decades highlights the need for the increased under-
standing of important influences and consequences as
well as research into developing preventive and treatment
strategies for sarcopenia [9].
Declines in muscle strength are driven, in part, by a
reduction in muscle mass which in turn is mediated by a
global reduction in myofibre number and myofibre atro-
phy [10,11]. There are several well known non-modifiable
and modifiable factors that influence adult skeletal mus-
cle mass and strength. These include age, gender, adult
body size, heritability, physical activity and nutrition [12-
16]. However, there remains considerable unexplained
variation in both muscle mass and strength in older peo-
ple that leads to the question of whether influences
occurring earlier in the life course such as developmental
influences are important in determining adult muscle
mass and strength. This life course approach potentially
widens the window for beneficial interventions in con-
trast to the current focus, which is on later life [17].
Observational epidemiological evidence exists for
developmental influences on muscle mass and strength in
middle aged as well as older adults, and has shown that
small size at birth (a proxy marker for an adverse intra-
uterine environment) is associated with reduced muscle
mass and strength [18-21]. Associations have been dem-
onstrated between size at birth and reduced fat free mass
using anthropometric indices [20], size at birth and
reduced muscle mass determined by urinary creatinine
excretion [22], body composition DXA [23], as well as
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directly measured size using pQCT [24]. The associations
between size at birth and muscle strength have been seen
in a few studies. For example, those conducted in the
Hertfordshire Cohort [19], in a middle-aged group of
men and women born in 1946 participating in the
National Survey of Health and Development [25] and in a
Finnish cohort of men and women born between1934
and 1944 [21]. Pooled data derived from 10 studies that
have investigated the relationship between lower birth
weight and reduced grip strength have revealed remark-
able homogeneity in this association with an effect size
estimate of a 2.06 kg increase in grip for every kg increase
in birth weight [26].
Interest is now focusing on the mechanisms underlying
these epidemiological associations and current research
aims to investigate whether the relationships are medi-
ated through skeletal muscle fibres, capillary density and/
or through alterations in anabolic or catabolic intracellu-
lar signalling pathways. Muscle fibre number is a critical
determinant of muscle mass and strength [27]. There is
strong evidence from animal studies for the effect of an
adverse intrauterine environment on the subsequent
number of myofibres in the fetus [27]. The majority of
these studies have use models of prenatal nutritional
manipulation with the observed effects on subsequent
myofibres dependent on the timing, nature and severity
of the insult.
Results from an ovine study showed peri-implanta-
tional and late gestational maternal under nutrition dif-
ferentially affected myofibre density and function in fetal
triceps muscle [28]. Both nutritional insults resulted in
decreased myofibre and capillary density with late gesta-
tional under nutrition predominantly causing a reduction
in type I, slow twitch, myofibre density. The effect of
under-nutrition on myofibre development and birth
weight has been seen in other animal models and there is
evidence that the effect of fewer myofibres has detrimen-
tal effects on muscle mass and meat quality in post-natal
life [29-32].
Molecular signals that govern hypertrophy include the
intracellular signalling molecules phosphatidylinositol-3-
phophate kinase, Akt and mammalian target of rapamy-
cin (PI3K/Akt/mTOR). These are part of a key signalling
pa th wa y activa t ed by upstr eam ligands, such as IGF-1,
that regulate myoblast proliferation in utero [33] as well
as muscle protein synthesis and hypertrophy in post-natal
life through increased protein transcription [34]. Con-
versely, inflammatory mediators such as IL-6 and TNF-α
can directly cause myocyte loss through activation of the
apoptotic pathways or through activation of the E3 ubiq-
uitin ligases Murine Ring Finger-1 (MuRF-1) and Muscle
Associated F-box (MAFBx/Atrogin-1) that are involved
in protein degradation [35].
There is limited evidence for an association between
small size at birth and change in muscle morphology or
imbalance in the anabolic and catabolic intracellular sig-
nalling pathways in human adults. One study of 20 low
birth weight and 20 normal birth weight men aged 19
years demonstrated a change in muscle fibre composition
and size [36]. Fewer type IIa (fast twitch) fibres were seen
(absolute fibre-count mean 43.4 vs 63.2 fibres, p = 0.004)
as well as an increase in type IIa fibre mean area (7444
μm2 vs 5754 μm2, p = 0.014) in the lower birth weight
group compared to higher birth weight group [46]. No
statistically significant differences were seen in type IIx
fibre number, area or, type I fibre number although the
type I fibres tended to be larger in the LBW group (5660
μm2 vs 4848 μm2). The authors suggest altered muscle
morphology may contribute to insulin resistance and
type II diabetes in the low birth weight men later in life
[36]. Another study investigating the relationship
between size at birth and muscle morphology in a group
of 27 adult women showed no changes in myofibre den-
sity, capillary density or muscle enzymatic activity [37].
There is observational evidence for the effect of inflam-
mation, mediated through cytokines such as IL-6 and
TNF-α, as a contributing factor to sarcopenia [38-40] and
that inflammation in adult life may be potentiated by
poor growth in early life [41].
The evidence from animal studies as well as the find-
ings from the study in young men with low birth weight
needs to be taken forward in studies of older people to
investigate the cellular and molecular mechanisms
underlying the developmental origins of sarcopenia. This
study takes the novel approach of collecting muscle tissue
in addition to data on muscle mass and strength in an
established birth cohort. A description of the study
design and methods now follows.
Design/methods
Study design
The Hertfordshire Sarcopenia Study (HSS) is a retrospec-
tive cohort study designed to investigate life course influ-
ences on muscle morphology, mass and strength in
community dwelling older people. It is part of the estab-
lished Hertfordshire Cohort Study (HCS) that comprises
a total of 2997 men and women born in Hertfordshire
between 1931 and 1939 and has previously been
described in detail [42]. From this total, 1086 men were
identified as potential HSS participants. After several
tiers of exclusion as detailed in Figure 1, a total of 375
men were invited to take part. Each participant's GP was
approached to ascertain the appropriateness of taking
part in HSS. One hundred and twenty participants were
visited at home by the study physician where require-
ments for the study were explained in detail, written
informed consent obtained and a health and activityPatel et al. BMC Geriatrics 2010, 10:43
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questionnaire administered. An appointment was then
made to attend the Wellcome Trust Clinical Research
Facility in Southampton General Hospital for further
investigations that involved an overnight stay. One hun-
dred and five men took part in the study and were fasted
overnight prior to their arrival to the research facility
(Figure 1). The study received ethical approval from the
Hertfordshire Research Ethics Committee (number 07/
Q0204/68).
Inclusion/exclusion criteria
Inclusion criteria for the study were availability of histori-
cal records of weight at birth and at one year. Participants
were excluded if they had a prior diagnosis of diabetes
mellitus, ischaemic heart disease, myopathy or any neu-
romuscular disorder that affected the legs. In addition,
participants who were on anticoagulants such as warfarin
were excluded. Female participants were not included in
this phase of the study.
Clinical measurements
Muscle biopsy
The participants were fasted overnight prior to muscle
biopsy. The semi-open muscle biopsy was performed
using a Weil Blakesley conchotome with a 6 mm biting tip
(Gebrüder Zepf Medizintechnik, Dürbheim, Germany)
(Figure 2) [43]. The left or right vastus lateralis muscle
was biopsied over the antero-lateral aspect of the thigh.
This site, approximately two-thirds down a line from the
anterior superior iliac spine to the patella, was readily
accessible and did not contain an overlying neurovascular
bundle. Following biopsy retrieval, the wound was closed
with steri-strips and an absorbent dry dressing was
placed over the wound after which, a two-layer compres-
sion bandage was applied for 6 hours. The procedure
took approximately 20 minutes to complete. Participants
were allowed to mobilize 30 minutes after the procedure
(Figure 2).
Tissue preparation and fixation
The biopsy tissue was divided and either processed for
morphological studies, or stored at -80°C for future
molecular study (e.g. gene expression studies). With
respect to morphological study, one sample piece was ori-
entated longitudinally under a dissecting microscope and
placed in 5 ml of cold acetone and allowed to fix
overnight in a freezer at -20°C before being embedded in
Glycol Methacrylate (GMA) [44] for later immunohis-
tochemical analyses (myofibre type, number, density
[fibres/mm2], area [μm2] and capillary density [capillar-
ies/mm2]). One sample was also orientated longitudinally
and fixed overnight at 4°C in 3% glutaraldehyde and 4%
formaldehyde solution before processing in resin for sub-
sequent electron microscopy studies.
Figure 1 Flow chart for the recruitment into the Hertfordshire 
Sarcopenia Study.
Figure 2 The muscle biopsy procedure. A. The leg was exposed 
from the groin crease down to the ankle. The biopsy area over the vas-
tus lateralis was shaved of hair, marked and isolated with a sterile drape 
that had a 10 cm aperture B. After the skin and subcutaneous tissue 
was infiltrated with local anaesthetic, the skin was punctured with a 
size 11 scalpel down to the fascia and the conchotome was inserted 
into the track made by the scalpel. The conchotome was rotated 
through 90° to cut the muscle C. Sustained pressure for 5 minutes was 
applied over the 5-10 mm incision to minimise bleeding D. The wound 
was closed with steri-strips and was dressed with absorbent dressing.Patel et al. BMC Geriatrics 2010, 10:43
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Dual energy X-ray absorptiometry (DXA)
A body composition DXA scan (Hologic Discovery, auto
whole body software version 12.5) was performed on all
p a r t i c i p a n t s  t o  q u a n t i f y  r e g i o n a l  a s  w e l l  a s  t o t a l  l e a n
mass, fat mass and bone mineral content.
Anthropometry
Weight was measured once to the nearest 0.1 kg. Height
was measured on a stadiometer (SECA, Hamburg, Ger-
many). A flexible, circumference measuring tape was
used to measure mid-upper-arm circumference, waist
circumference; at a point mid-way between the costal
margin and the iliac crest in the mid-axillary line, hip cir-
cumference; at the widest part of the hip between the
greater trochanter and the lower buttock level. Mid-thigh
circumference was measured at a point half way between
the protuberance of the greater trochanter and a circum-
ferential line drawn at the upper border of the patella. All
measurements were read to the nearest 0.1 cm. Skinfold
measurements were taken in triplicate from the triceps,
biceps, sub-scapular and upper supra-illiac regions using
a standard calliper (Crymych, Holtain Ltd, UK). Measure-
ments were all of the non-dominant side. Blood pressure
was measured on the right arm with a digital device
(DASH 3000, GE Medical systems, USA) and a standard
12 lead electrocardiogram was taken and interpreted to
identify any occult ischaemic heart disease or cardiac
arrhythmia.
Grip strength
Isometric grip strength was measured three times in each
hand, alternating between right and left hands, using a
Jamar handheld hydraulic dynamometer (Promedics,
UK) with the participant seated. The dynamometer was
supported, but not held by the investigator during testing.
The maximum of six measurements to the nearest 1 kg
was used in subsequent analyses [45].
Physical performance measures and aerobic fitness
A validated battery of tests was used to assess motor
function that included: five timed chair rises, a 6 metre
timed up-and-go where participants were asked to stand
from sitting, walk 3 metres, turn around and return back
to the seated position; customary walking speed over 3
metres, and standing balance, where participants were
timed standing on one leg with eyes open [46-48]. A sub-
maximal exercise test was performed on a stationary
cycle ergometer. The starting workload was 25 watt,
which was maintained for 3 minutes, thereafter the work-
load increased by 10 watts every minute. The test was
stopped if the participants reached 80% of the maximum
age predicted heart rate, a respiratory exchange ratio of
1.1; signifying their anaerobic threshold, or the partici-
pants wanted to stop. Gas parameters were measured for
3 minutes after stopping the test. Oxygen consumption
(VO2), expired carbon dioxide (VCO2) and volume of
expired air (VE) were determined through breath-by-
breath analyses using a Metalyser 3B gas analyser system
(Cortex Biophysik, Cranleigh and Co., Birmingham, UK)
[49]. Heart rate was monitored through a Polar receiver
(Polar Electro UK, Ltd).
Blood collection
Fasting blood samples were taken from the anterior
cubital fossa for subsequent glucose, insulin, HbA1c, hor-
monal, inflammatory and DNA analyses. A total of 40 ml
were collected in two plain (10 ml each) lithium heparin
(10 ml), EDTA (5 ml) and fluoride oxalate (5 ml) tubes
(Vaccutainer Systems, Beckton Dickinson, UK). All
except the EDTA tube were centrifuged at 2500 rpm for
15 minutes at 4°C. Respective serum, plasma and fluoride
oxalate aliquots were prepared in 1 ml tubes and frozen at
-80°C until further analyses. The supernatant from the
EDTA tube was discarded and the residue (clot/whole
blood) was pipetted into 1 ml aliquots and stored at -80°C
until further analyses.
Questionnaires
Health and activity
A general health questionnaire was used to record details
of smoking and alcohol habits, co-morbidity, medication
use and lifestyle. The present questionnaire was based on
questionnaires used previously in the cohort that had also
ascertained participants' social class and dietary habits.
Cognitive function
An AH4 test to determine intelligence quotient as well as
the Mill Hill vocabulary test were administered to test
decline in cognitive function [50].
Study feedback
All participants were asked to provide feedback one week
after the clinic visit. The feedback questionnaire consists
of 12 anonymous questions about their experience of the
study and specifically, their experience of the muscle
biopsy.
Investigations completed thus far
One hundred and twenty subjects consented to take part
in the study (Figure 1). Home visits were arranged for all
120 participants where written informed consent was
obtained, a health and activity questionnaire adminis-
tered and WTCRF clinics arranged in Southampton. Fif-
teen participants withdrew after the home visit because
of ongoing hospital investigations, time constraints or
were caring for their spouse. Subsequently, 105 partici-
pants, with a mean age of 72.5 years were seen in WTCRF
clinics over the course of 14 months (October 2007 -Patel et al. BMC Geriatrics 2010, 10:43
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December 2008). Three participants were seen on any
one clinic. The strength and body composition measures
of the study sample are presented in Table 1. The mean
height was 174.2 cm (range 157.6-193.7), mean weight
82.8 kg (58.1-118.8), body mass index (BMI) 27.2 kg/m2
(18.6-38.3), birth weight 3.5 kg (2.3 - 5.4), weight at one
year 10.3 kg (7.7-12.7), grip strength 38.7 kg (18-66). The
total lean body mass was derived from DXA and was 56.5
kg (42.7-75.9); the appendicular skeletal mass represents
the total lean mass of four limbs and was 24.2 kg (16.9-
33.7). Fat mass was also calculated from DXA and was a
mean of 22.7 kg (range 5.6-46.2).
One hundred and two muscle biopsies were success-
fully obtained with a Weil Blakesley conchotome using a
standard aseptic protocol. The three participants who
were not eligible for the biopsies were on treatment that
could have influenced wound healing (n = 2) or predis-
pose to haematoma formation (n = 1). The mean biopsy
mass from 53 samples was 107 mg (range 20 to 290 mg) -
sufficient for subsequent histological, electron micros-
copy and molecular studies.
Anthropometry, measures of muscle function (grip
strength and physical performance) and venesection was
completed on all 105 participants according to protocol.
Eighty-four participants completed the sub-maximal
exercise test: ten participants did not complete the test
fully and 11 participants were excluded from the test
(ECG abnormality n = 6 or were on medication that arti-
ficially lowered heart rate e.g. β blockers, n = 5).
All 105 participants completed the health and activity
questionnaires and 98 participants completed both the
AH4 and Mill Hill tests. Ninety-three participants pro-
vided complete feedback questionnaires. Thirty-four
(37%) of the participants found the biopsy procedure bet-
ter than expected, 52 (56%) as they had expected and 7
(7%) worse than expected. All participants were mobile
within half an hour of the procedure without any diffi-
culty and 60 (65%) of the participants resumed their nor-
mal daily activity the next day (but avoided vigorous
activity). Thirty-three (35%) participants were back to
their usual activity after two days. There were no serious
wound complications and there was full healing within a
week. Eighty-five (91%) of the participants were willing to
have the biopsy again for research purposes [43].
No adverse incidents occurred during the course of the
study. All participants received detailed feedback on clin-
ically relevant parameters (ECG, bone mineral density
and blood pressure) that were also fed back to their Gen-
eral Practitioners.
Statistical analyses
All data will be analysed using STATA release 10 (STATA
Corp, Texas, 2009). Normality of variables will be
assessed using visual inspection of histograms and tests
of skewness and kurtosis. Variables will be loge trans-
formed as necessary. Variables will be summarised using
means and standard deviations (SD), medians and inter-
quartile ranges (IQR) for continuously distributed vari-
ables and frequency and percentage distributions for cat-
egorical variables. The relationships between birth
weight and muscle morphology mass and function will be
principally explored using the Student's t-test or analysis
of variance (ANOVA), and linear regression. Multiple lin-
ear regression will be used to adjust for the potential con-
founding influence of age, anthropometry, physical
activity, lifestyle, co-morbidity and medication use.
The relationships between life course influences and
muscle morphology, mass and function will be explored
using the Student's t-test, ANOVA or Pearson's correla-
tion coefficient followed by linear and multiple regres-
sion. The inter-relationships between muscle
morphology, mass and strength will similarly be deter-
mined using Pearson's correlation coefficient and linear
regression.
Sample size
Sample size calculations assumed a standard deviation of
22.0 for type IIa fibre number based on a previous study
in young men and showed that a study of 50 lower birth
weight and 50 higher birth weight men would have 80%
power, at the 5% significance level, to declare means of
type IIa fibre number of 56 and 45 between groups statis-
tically different.
Discussion
There is a growing body of epidemiological evidence sup-
porting an association between birth weight and adult
Table 1: Hertfordshire Sarcopenia Study participant 
characteristics
Study sample
n = 105
Mean SD Min Max
Age (years) 72.5 2.5 68.3 77.4
Height (cm) 174.2 6.7 157.6 193.7
Weight (kg) 82.8 12.6 58.1 118.8
BMI (kg/m2) 27.2 3.6 18.6 38.3
Birth weight (kg) 3.5 0.7 2.3 5.4
Weight at one (kg) 10.3 1.1 7.7 12.7
Grip strength (kg) 38.7 8.4 18 66
Total body lean mass (kg)DXA 56.5 6.7 42.7 75.9
Appendicular skeletal mass (kg)DXA 24.2 3.2 16.9 33.7
Fat mass (kg)DXA 22.7 6.8 5.6 46.2Patel et al. BMC Geriatrics 2010, 10:43
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mass and strength. However the underlying mechanisms
are not known and there are few studies in this area. One
study involved a small number of older women and
another, 40 young men. In contrast the HSS involves over
100 older men and future research will include both
Hertfordshire men and women. Previous experience
from the Hertfordshire Physical Activity Trial suggests
that healthy community dwelling older women are willing
to have a muscle biopsy alongside more routine assess-
ment of body composition [51]. No adverse complica-
tions arose as a result of the muscle biopsy in this study.
This novel study will allow the determination of poten-
tial cellular and molecular mechanisms that underlie the
evidence linking life course influences and sarcopenia.
This will be achieved through study of muscle tissue
obtained by biopsy in addition to obtaining usual mea-
surements on muscle mass, strength and aerobic fitness
in a group of community dwelling older men aged 68 to
76 years with records of birth weight and weight at one
year . W e have already shown that muscle biopsy of the
vastus lateralis by the conchotome technique is both fea-
sible and acceptable in this group [43]. The study findings
will not only consolidate our understanding of the
changes in muscle that occur with age and their relation-
ship to early growth but will also have the potential to
inform the development of beneficial interventions to
implement across the life course.
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